Key terms
About VNDA
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VNDA news
Mar 06
7:05am ET
Vanda Pharmaceuticals receives CRL from FDA regarding sNDA for HETLIOZ
Feb 21
4:44pm ET
Vanda Pharmaceuticals Sets New Executive Compensation Packages
Feb 06
4:50am ET
Vanda Pharmaceuticals Shares HETLIOZ® FDA Review Progress
Feb 05
8:04am ET
Vanda Pharmaceuticals announces FDA update for supplemental NDA for Hetlioz
Jan 31
9:04am ET
Vanda Pharmaceuticals: FDA approves IND application to evaluate VTR-297
Jan 30
12:38pm ET
Court orders FDA to resolve Vanda’s jet lag hearing request by March 4
Jan 29
7:03pm ET
Court orders FDA to resolve Vanda Pharmaceuticals’ hearing request on HETLIOZ
Jan 26
5:35am ET
Vanda Pharmaceuticals announces U.S. patent allowance for Ponvory
Jan 25
1:09pm ET
Vanda announces publication of journal article on Tradipitant study
Jan 23
9:18am ET
Vanda Pharmaceuticals’ IND application for VCA-894A granted FDA approval
Jan 19
3:58pm ET
Vanda Pharmaceuticals says court denied in part U.S. motion to dismiss
Jan 17
3:49pm ET
Vanda announces publication of journal article on Fanapt study
Jan 12
12:25pm ET
Vanda comments on FDA’s recently announced guidance on communication
No recent news articles are available for VNDA
VNDA Financials
Key terms
Ad Feedback
VNDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VNDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range